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1668Objective: Bone marrow–derived mesenchymal stem cells (MSCs) have shown therapeutic potential in acute
lung injury. Recently, placenta-derived human mesenchymal stem cells (PMSCs) have shown similarities
with bone marrow–derived MSCs in terms of regenerative capabilities and immunogenicity. This study
investigates the hypothesis that treatment with PMSCs reduces the development of bronchiolitis obliterans in
a murine heterotopic tracheal transplant model.
Methods: A murine heterotopic tracheal transplant model was used to study the continuum from acute to
chronic rejection. In the treatment groups, PMSCs or PMSC-conditioned medium (PMSCCM) were injected
either locally or intratracheally into the allograft. Phosphate-buffered saline (PBS) or blank medium was in-
jected in the control groups. Tracheal luminal obliteration was assessed on sections stained with hematoxylin
and eosin. Infiltration of inflammatory and immune cells and epithelial progenitor cells was assessed using
immunohistochemistry and densitometric analysis.
Results:Compared with injection of PBS, local injection of PMSCs significantly reduced luminal obliteration at
28 days after transplantation (P¼ .015). Intratracheal injection of PMSCs showed similar results to local injec-
tion of PMSCs compared with injection of PBS and blank medium (P ¼ .022). Tracheas treated with PMSC/
PMSCCM showed protection against the loss of epithelium on day 14, with an increase in P63þCK14þ epithe-
lial progenitor cells and Foxp3þ regulatory T cells. In addition, injection of PMSCs and PMSCCM significantly
reduced the number of neutrophils and CD3þ T cells on day 14.
Conclusions: This study demonstrates that treatment with PMSCs is protective against the development of
bronchiolitis obliterans in an heterotopic tracheal transplant model. These results indicate that PMSCs could
provide a novel therapeutic option to reduce chronic rejection after lung transplant. (J Thorac Cardiovasc
Surg 2014;147:1668-77)Supplemental material is available online.
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The Journal of Thoracic and Cardiovascular Surthe single most important cause of late mortality after lung
transplantation, affecting up to 50% of patients 5 years after
transplantation.1,2 Despite remarkable progress in improving
outcomes through the refinement of surgical technique and
the use of more effective immunosuppressive regimens,
BO still affects most lung transplant recipients by 5 years;
no treatment options have shown beneficial effects for
preventing or slowing the progress of this disease.1,2
Therefore, innovative and effective therapies (such as
molecule- and cell-based therapies) to prevent and attenuate
the development of BO are urgently needed.
Mesenchymal stem cells (MSCs) originating from the
bone marrow have been used as a therapeutic strategy in
several invivomodels of acute lung injury, including bleomy-
cin-induced,3 intraperitoneal and intratracheal Escherichia
coli endotoxin–induced4,5 and lipopolysaccharide-induced6
acute lung injury. Recent research has provided clear evi-
dence that MSCs have great potential as a cell-based therapy
for acute lung injury due to several features, including (1)
secretion of multiple paracrine factors, including keratino-
cyte growth factor,7 interleukin (IL)-1 receptor antagonist
(IL-1RA),8 granulocyte colony-stimulating factor (G-CSF),
and granulocyte macrophage colony-stimulating factorgery c May 2014
Abbreviations and Acronyms
BO ¼ bronchiolitis obliterans
DAPI ¼ 4,6-diamidine-2-phenylindole
dihydrochloride
G-CSF ¼ granulocyte colony-stimulating
factor
GM-CSF ¼ granulocyte macrophage
colony-stimulating factor
H&E ¼ hematoxylin and eosin
HPF ¼ high-power field
HTT ¼ heterotopic tracheal transplant
IL ¼ interleukin
IL-1RA ¼ interleukin 1 receptor antagonist
MSC ¼ mesenchymal stem cells
PBS ¼ phosphate-buffered saline
PMSC ¼ placenta-derived human
mesenchymal stem cells
PMSCCM ¼ PMSC-conditioned medium
TNF ¼ tumor necrosis factor
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the mobilization of endogenous stem cells into the blood
circulation; (2) blocking of inflammatory cytokines, such as
interferon-g, IL-2, IL-1b, IL-4, macrophage inflammatory
protein-2, and tumor necrosis factor (TNF)-a,3,7 all
fundamental proinflammatory cytokines involved in lung
injury; (3) immunosuppressive effects, by inhibiting the
activity of innate and adaptive immune cells10,11; (4)
alteration of the endothelial and epithelial permeability of
the lung5,12; (5) reduction of edema by restoring alveolar
fluid clearance.7
Recently, human placenta-derived MSCs (PMSCs) have
been isolated, characterized, and studied by various labora-
tories. PMSCs not only express common MSC surface
markers such as CD11a, CD29, CD44, CD73 CD90,
CD105, CD146, CD166, and HLA-ABC but also have the
ability to differentiate into adipogenic, chondrogenic, and
osteogenic lineages under the proper conditions.13,14
Compared with bone marrow–derived MSCs, PMSCs are
more easily obtained and are available in large numbers.
Because they have similar properties and effects as bone
marrow–derived MSCs, they are becoming a promising
alternative source of MSCs in basic research and clinical
applications. In the recent literature, PMSCs have been
shown to have immunosuppressive properties by suppressing
the activation and proliferation of T lymphocytes.15,16 In
addition, PMSCs show minimal to no immunogenicity.17
Because of these unique properties of PMSCs, the pre-
sent study was designed to explore the use of PMSCs as a
novel treatment to prevent the development of BO. We
hypothesized that local treatment with PMSCs or PMSC-
conditioned medium (PMSCCM) suppresses inflammatoryThe Journal of Thoracic and Carand immunologic cascades and reduces the development of
BO in a murine heterotopic tracheal transplant (HTT)
model.
MATERIALS AND METHODS
Culture of Human PMSCs
PMSCs18 were obtained from the laboratory of our collaborator, Dr
Michael P. Murphy (Indiana University School of Medicine, Indianapolis,
Ind). The PMSCs were grown in Dulbecco’s modified Eagle’s medium/
F12K (1:1) medium (Gibco BRL, Life Technologies, Rockville, Md) sup-
plemented with 10% fetal bovine serum and 1% of penicillin/streptomycin
in a humidified incubator containing 5% CO2 at 37
C. When the cell den-
sity reached 90% confluence, the conditioned medium was collected and
centrifuged at 1000 rpm to remove the debris. After washing with warm
13 phosphate-buffered saline (PBS), the cells were detached with
0.05% Trypsin-EDTA and centrifuged at 600 rpm. The harvested cells
were then washed with 13 PBS twice. The cells were counted using a Cell-
ometer Auto 2000 (NexcelomBioscience LLC, Lawrence,Mass). The cells
were diluted in 13 PBS (1 3 107) and put on ice until they were injected.
Mice
The experimental mice were purchased from Jackson Laboratory (Bar
Harbor, Maine). The Animal Care and Use Committee at the University
of Virginia approved all aspects of the experimental protocol before exper-
imentation. All experimental mice received humane care in accordance
with The Principles of Laboratory Animal Care and The Guide for the
Care and Use of Laboratory Animals.
Experimental Groups
The mouse HTT model was used as described previously.19 Male
BALB/c mice were used as donors and C57BL/6 mice as recipients (22-
27 g). Each recipient mouse received 4 different donor tracheas trans-
planted subcutaneously. The recipient mice were randomly divided into
6 groups: group 1, PMSC cells (13 106 cell in PBS) were injected locally
into the subcutaneous area surrounding the transplanted trachea on day 1
after transplantation (4 recipient mice/time point); group 2, the same vol-
ume of PBS was injected locally as a control for group 1; group 3,
PMSC cells (1 3 105 cell in PBS) were injected directly into the lumen
of the transplanted trachea on day 3 after transplantation (4-7 mice/time
point); group 4, the same volume of PBS was injected directly into the
lumen of the transplanted trachea on day 3 after transplantation as a control
of group 3 (3 mice/time point); group 5, PMSC-CM was injected directly
into the lumen of the transplanted trachea on day 3 after transplantation (4-
6 mice/time point); group 6, the same volume of blank medium was in-
jected directly into the lumen of the transplanted trachea on day 3 after
transplantation as a control for group 5 (3 mice/time point). The intratra-
cheal injections were performed as previously described.20 The recipient
mice were killed and the allografts were harvested on day 7, 14, or 28
for histology and immunohistochemical staining.
Histology and Immunohistochemical Staining
The harvested allograft specimens were immediately fixed in 10%
formalin. After 24 hours, fixed tracheas were embedded in paraffin and sec-
tions were stained with hematoxylin and eosin (H&E) or stained by
immunohistochemistry.
Immunohistochemical staining of mouse migratory
macrophages and neutrophils. Staining for mouse migratory
macrophages and neutrophils was performed as described previously.19,20
Briefly, rat antimouse neutrophil antibody (AbD Serotec, Raleigh, NC)
and rat antimouse Mac-2 antibody (Accurate Chem, Westbury, NY) were
used as primary antibodies. Alkaline phosphatase-conjugated donkey anti-
rat IgG (Sigma, St Louis, Mo) was used as a secondary antibody. Thediovascular Surgery c Volume 147, Number 5 1669
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normal rat IgG (eBioscience Inc, San Diego, Calif) was used for negative
controls.
Immunohistochemical staining of mouse CD3þ T cells
and Foxp3þ regulatory T cells. Stainingwas performed accord-
ing to our previous publications.19 Briefly, after antigen unmasking and
blocking, goat antimouseCD3ε antibody (Santa Cruz Biotechnology, Santa
Cruz, Calif) and polyclonal rabbit antimouse Foxp3 primary antibody (Ab-
cam Inc, Cambridge, Mass) were used to detect CD3þ T cells and CD4þ/
CD25þ/Foxp3þ regulatory T cells. After incubation with biotin-SP-
conjugated secondary antibodies and an avidin-biotin complex (Vectastain
ABC kit, Vector Laboratories, Burlingame, Calif), immunoreactivity was
visualized by incubating the sections with 3,3-diaminobenzidine tetrahy-
drochloride (DAKO Corporation, Carpinteria, Calif) to produce a brown
precipitate, and counterstained with hematoxylin. The infiltrated CD3þ
T cells and Foxp3þ regulatory T cells were counted and used for statistical
analysis.
The number of positive stained cells (neutrophils, macrophages, CD3þ
T cells, and Foxp3þ regulatory T cells) per high-power field was assessed
via immunohistochemical staining of tracheal sections; 4 fields were
counted per trachea. To ensure the validity of all cell counts, counting of
positively stained cells was performed in a blind manner by a separate
investigator. The average cell number was used for statistical analysis.
Immunofluorescence staining of tumor protein P63 and
cytokeratin 14. The immunofluorescence staining of P63 and cytoker-
atin 14 (CK14) was performed according as described previously.21 Briefly,
paraffin sections were deparaffinized, rehydrated, and stained overnight at
4C with rabbit antimouse P63 (1:750) and guinea pig antimouse CK14
(1:200) (Lifespan BioSciences Inc, Seattle, Wash). Purified normal rabbit
and guinea pig IgGs were used as negative controls. Secondary fluorescein
isothiocyanate–conjugated donkey antirabbit IgG and Cy5-conjugated goat
antiguinea pig IgG were subsequently applied at a 1:2000 dilution for 1
hour at room temperature. The cell nucleus was stained with 4,6-diamidine-
2-phenylindole dihydrochloride (DAPI; Roche Diagnostics,Mannheim, Ger-
many). Images were viewed and saved using an Olympus BX51 microscope
equipped with an Olympus DP70 digital camera (Minneapolis, Minn).
Immunocytochemical staining of human HLA-ABC in
PMSCs. Immunocytochemical staining was performed according to
our previous publication.21 Briefly, PMSCs were fixed in 50% methanol/
50% acetone for 15 minutes and permeated with 1% Triton X-100 in
Tris-buffered saline for 15 minutes. Nonspecific antibody binding in cells
was blocked with blocking buffer (5% nonfat milk and 10% normal
donkey serum in Tris-buffered saline with 0.1% Tween-20) for 1 hour at
room temperature before overnight incubation with specific rabbit anti-
human HLA-ABC antibody (Abcam) in the same buffer (4 mg/mL) at
4C. Cells were then incubated with alkaline phosphatase–conjugated sec-
ondary antibody (Jackson ImmunoResearch, West Grove, Pa) diluted
(1:2000) in blocking buffer for 1 hour at room temperature. The signals
were detected by adding Fast Red. Purified preimmune IgGs from the
same animal were used as negative controls. The sections were counter-
stained lightly with hematoxylin and DAPI (1 mg/mL) for viewing nega-
tively stained cells.
Measurement of Tracheal Luminal Obliteration
Allograft tracheal tissue was fixed, embedded, sectioned, and stained
with H&E. Allograft trachea sections were photographed at 43magnifica-
tion. The luminal obliteration was semiquantified using ImageJ software as
described in our previous publications in a blinded fashion.19,20 Six to 20
allografts were measured in each group.
Statistical Analysis
Statistical differences between 2 groups were determined using the
Student t test. Data were reported as the mean standard error of the mean.1670 The Journal of Thoracic and Cardiovascular SurRESULTS
Injection of PMSCs and PMSCCM Attenuated BO
on Day 28
Intratracheal delivery of PMSCs significantly reduced
the development of BO on day 28 (65.85%  2.99% vs
95.62%  0.76%, P ¼ .021; Figure 1). Furthermore, to
explore the effects of PMSC-derived soluble paracrine fac-
tors on the development of BO, PMSCCM was injected in-
tratracheally. Intratracheal delivery of PMSCCM showed a
trend for reduced development of BO, but this was not sig-
nificant compared with blank medium controls (62.09% 
4.24% vs 82.70%  3.04, P ¼ .212; Figure 1). Similar to
the results for intratracheal injection, local injection of
PMSCs significantly reduced luminal obliteration at 28
days after transplantation (64.38%  8.14% vs 98.78%
 3.63%, P ¼ .015, n ¼ 8 tracheas per group) compared
with controls injected with PBS (Figure E1).Injection of PMSCs and PMSCCMProtected Against
Epithelial Loss on Day 14
Our previous publication20 reported that secondary loss
of luminal epithelial integrity was a key factor preceding
BO development. Therefore, the potential function of
PMSCs to prevent this secondary epithelial loss was evalu-
ated. The allografts treated with PMSCs were significantly
protected against the secondary loss of intraluminal epithe-
lium on day 14 compared with the controls injected with
PBS (17.88%  2.82 vs 98.75%  0.24% circumferential
epithelial loss, P<.001) (Figure E2). The effects of intratra-
cheal treatment with PMSCs and PMSCCM on the integrity
of epithelial cells within the allografts were then deter-
mined. Both PMSC- and PMSCCM-treated tracheas were
significantly protected against the secondary loss of intralu-
minal epithelium on day 14 compared with the tracheas
treated with PBS (55.68%  2.62% vs 79.98% 
2.43%, P ¼ .011) or blank medium (28.51%  6.18% vs
74.84%  3.99%) (Figure 2).Injection of PMSCs and PMSCCM Blocked
Neutrophil and CD3þ T-Cell Infiltration and
Increased Macrophage and Foxp3þ Regulatory
T-Cell Infiltration on Day 14
The effects of PMSCs on the infiltration of inflammatory
cells in the allografts were explored. As shown in Figure 3,
PMSC-treated samples had significantly less neutrophil
infiltration compared with saline controls (4,982,429 
1,245,992 units vs 11,015,522  5,113,617, P ¼ .001) on
day 14 after tracheal transplantation. In contrast, injection
of PMSCs increased macrophage infiltration in the same
samples (18,264,767  5,949,626 vs 11,554,467 
6,472,769, P¼ .056). Furthermore, PMSC treatment signif-
icantly decreased CD3þ T-cell infiltration in the allografts
on day 14 (83.33  18.61 vs 51.25  17.46, P ¼ .006,gery c May 2014
FIGURE 1. Intratracheal injection of PMSCs and PMSCCM attenuated the development of BO on day 28 after tracheal transplantation. A, Representative
images of H&E staining of the allograft 28 days after transplantation. The magnification of all images is 43. þPMSCs, Treated with PMSCs (1 3 106);
þPBS, treated with 13 PBS as the control; þPMSCCM, treated with PMSCCM; þCONM, treated with blank medium as the control. B, Bar graph of
luminal obliteration of the allografts with PMSC (n ¼ 13) and PMSCCM (n ¼ 8) on day 28. Data shown are the mean  standard error of mean.
PMSC, Placenta-derived human mesenchymal stem cells; PBS, phosphate-buffered saline; PMSCCM, PMSC-conditioned medium; CONM, control media.
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Foxp3þ regulatory T cells on day 14 after tracheal trans-
plantation compared with saline controls (14.17  4.96 vs
21.56  7.52, P ¼ .036, Figure E3, B).Intratracheally Injected PMSCs Did Not Integrate
Into the Luminal Epithelial Layer
We next tried to elucidate whether PMSC engraftment
into the luminal epithelium contributed to the epithelial
integrity seen with intratracheal injection of PMSCs. Using
immunocytochemical staining, we showed that PMSCs areThe Journal of Thoracic and CarHLA-ABC positive (Figure 4, A). HLA-ABC staining for
the human PMSCs revealed that PMSCs did not integrate
into the epithelial layer in this experimental model
(Figure 4, B).Injection of PMSCs and PMSCCMProtected Against
Epithelial Loss by Promoting P63þCK14þEpithelial
Progenitor Cells and Increasing Foxp3þ Regulatory
T Cells
To further explore the mechanism of PMSC protection
against epithelial loss, we determined the expression levelsdiovascular Surgery c Volume 147, Number 5 1671
FIGURE 2. Loss of epithelial cells in allografts after intratracheal injection of PMSCs or PMSCCM on day 14 after transplantation. A, Representative
images of H&E-stained histopathologic sections of allografts at 14 days after transplantation. All images are 403 magnification. þPMSCs, Treated
with PMSCs (13 106); þPBS, treated with 13 PBS as control; þPMSCCM, treated with PMSCCM; þCONM, treated with blank medium as the control.
B, Bar graph depicting percentage allograft luminal epithelial loss with each type of injection (n¼ 7-13). Data shown are the mean standard error of mean.
PMSC, Placenta-derived human mesenchymal stem cells; PBS, phosphate-buffered saline; PMSCCM, PMSC-conditioned medium; CONM, control media.
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and CK14, within the PMSC-treated and saline-treated allo-
grafts using immunofluorescence staining. Both P63 and
CK14 are believed to be markers of basal epithelial progen-
itor cells found within mouse and human trachea and
lung,22,23 As shown in Figure 5 and Figure E4, intratracheal
administration of PMSCs and PMSCCM obviously
increased P63 and CK14 double-positive cells compared
with PBS or blank medium controls. In addition, adminis-
tration of PMSCs and PMSCCM increased Foxp3þ1672 The Journal of Thoracic and Cardiovascular Surregulatory T cells compared with PBS or blank medium
controls (14.08  2.31 vs 6.75  2.49, P < .001)
(Figure E5).
DISCUSSION
The importance of bone marrow–derived MSCs in acute
lung injury has been well documented in in vitro, ex vivo,
and in vivo models.3-11 Because ischemia-reperfusion
injury is one of the major contributors for the development
of BO1,24 and PMSCs showed similar characteristics andgery c May 2014
FIGURE 3. Immunofluorescent staining and densitometric analysis of macrophage and neutrophil infiltration in the allografts treated with PMSCs and PBS
controls on day 14. A, Representative images of immunofluorescent staining of the allograft 14 days after transplantation. Red color indicates positive-
staining signals. Blue color indicates nuclei stained with DAPI. The magnification of all images is 203. B, Bar graph of macrophage and neutrophil infil-
tration in the allografts treated with PMSCs and PBS on day 14. Data shown are the mean standard error of mean. n¼ 8.þPMSCs, Treated with PMSCs
(1 3 106); þPBS, treated with 13 PBS as control; HPF, high-power field; PMSC, placenta-derived human mesenchymal stem cells; PBS, phosphate-
buffered saline.
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hypothesis that PMSCs may halt progression towards
luminal obliteration in a well-established mouse HTT
model. The results demonstrated that PMSCs indeed atten-
uated the development of BO on day 28 after tracheal trans-
plantation compared with control groups. This study is the
first to show that PMSCs and PMSCCM attenuate the devel-
opment of BO through, at least in part, protection ofThe Journal of Thoracic and Carepithelial integrity at the cellular level. Recently, Grove
and colleagues25 performed a similar study to investigate
treatment with bone marrow–derived MSCs via retro-
ocular injection in the HTT model. In concordance with
our results, they found a reduction in intraluminal collagen
deposition after treatment with bone marrow–derived
MSCs, as well as a reduction in transforming growth factor
b levels and an increase in IL-10 levels.diovascular Surgery c Volume 147, Number 5 1673
FIGURE 4. PMSCs failed to integrate into the airway epithelial layer on day 14 after transplantation after intratracheal delivery. A, Representative
images of immunofluorescent staining of human HLA-ABC within in vitro PMSCs. The images were taken at 203 magnification. Red color indicates
positive staining of human HLA-ABC, blue color indicates nuclei stained with DAPI. B, Representative images of immunofluorescent staining
of human HLA-ABC and CK14 within tracheas treated with PMSCs. The images were taken at 403 magnification. Red color indicates positive
staining of human HLA-ABC molecules (left panel) and CK14 molecules (right panel); blue color indicates nuclei stained with DAPI.
Right, The location of epithelial cells is seen by the area of strong CK14 signal. Left, There is essentially no HLA-ABC signal in this same location.
HLA-ABC, Human leukocyte antigens-A, -B, and -C.
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FIGURE 5. Double immunofluorescent staining of P63 and CK14 in the tracheal allografts treated intratracheally with PMSCs or PBS on day 14 after trans-
plantation. Red color indicates positive staining of CK14; green color shows positive staining of P63; blue color indicates nuclei stained with DAPI. The magni-
fication of all images is 403. Themerged images are indicated on the side.þPMSCs, Intratracheally treated with PMSCs (13 106);þPBS, treatedwith 13 PBS
as control. PMSC, Placenta-derived human mesenchymal stem cells; PBS, phosphate-buffered saline; DAPI, 4,6-diamidine-2-phenylindole dihydrochloride.
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markers (p63 and CK14) was also seen after PMSC and
PMSCCM treatment. Our previous publication20 showed
that injection of epithelial stem/progenitor cells into the al-
lografts on day 3 after transplantation blocked the loss of
epithelial cells within the allografts, which is a key factor
for the development of BO. Many different cellular pro-
cesses have been linked to p63 regulation in epithelial cells,
including cell proliferation, survival, differentiation,
apoptosis, cell fate specification, maturation of epithelial
progenitor/stem cells, as well as cell-cell and cell-matrix
interaction events.22,23 Our current results further confirm
our previous findings that the integrity of epithelial cells
is critical for preventing the progression of BO. These
results are in agreement with other publications, showing
that epithelial cells play an important role in the
development of BO26,27 Therefore, PMSCs and PMSCCM
may provide a novel therapeutic strategy to reduce BO
after lung transplantation by promoting epithelial
progenitor cells.
Local injection of PMSCs specifically inhibited neutro-
phil infiltration. Surprisingly, PMSCs increasedmacrophage
infiltration under the same treatment. A recent publication
showed that lung-resident tissue macrophages generate
Foxp3þ regulatory T cells and promote airway tolerance.28
Moreover, injection of PMSCCM also had similar effects on
neutrophil infiltration compared with injection of PMSCs.
Using a bleomycin-induced lung injurymodel,Ortiz and col-
leagues3,8 found that MSCs protect lung tissue from injury
by blocking TNF-a and IL-1. Xu and colleagues4 also
showed that MSCs prevented endotoxin-induced lung
inflammation, injury, and edema. Several mouse injury
models5,8 have shown that PMSC treatment affects the
secretion of antiinflammatory cytokines, such as IL-1RA,
IL-10, and angiopoietin-1. Therefore, a single injection of
PMSCCM may reduce proinflammatory cytokines, which
subsequently leads to less infiltration of inflammatory cells
and immune cells. We have shown that T cells are critical
for epithelial protection, because secondary loss of epithe-
lium does not occur in the HTT model.20 Our previous pub-
lication showed that loss of epithelium is another essential
factor for the development of BO.20 Because the half-life
of cytokines is generally short, PMSCCMs were collected
just before injection. Therefore, it is highly possible that a
single injection of PMSCs/PMSCCM acts as an initiator to
start this cascade of processes.
To further elucidate the possibility that PMSCs may suc-
cessfully engraft into regenerated luminal tracheal epithe-
lium, PMSCs were injected intratracheally on day 3,
which is a critical time window for epithelial regeneration.
As shown in Figure 5, the intratracheal injection of PMSCs
did not engraft into the epithelial layer of allografts in this
model. In contrast to our findings, Zhen and colleagues29
and Yamada and colleagues6 found that MSCs were able1676 The Journal of Thoracic and Cardiovascular Surto engraft in recipient lungs and differentiate into type II
alveolar epithelial cells. These results strongly suggest
that PMSCs and PMSCCM may have effects on epithelial
maintenance and the development of BO through a para-
crine mechanism rather than direct engraftment. Because
the treatment with PMSCs can be substituted with
PMSCCM, which contains many biological factors (such
as cytokines, growth factors, and so forth), it will be
much easier to apply to patients after lung transplantation
by inhaling or pretreating the donor lung before the
transplantation.
Using a mouse HTTmodel with Rag-1 KOmice, we have
shown that immune cell-mediated activitywas key in the sec-
ondary loss of epithelial cells.20 With this knowledge, we
next explored the potential function of PMSCs/PMSCCM
as an immune modulator and/or regulator during BO forma-
tion. The results demonstrate that intratracheal injection of
PMSCs and PMSCCM significantly suppress CD3þ T-cell
infiltration on day 14 after tracheal transplantation. These re-
sults suggest that PMSCs andPMSCCMmayact as an immu-
nosuppressor during the cellular infiltration phase of BO
development. Several publications have suggested that
PMSCs have the ability to suppress T-cell proliferation and
activation.15-17,30,31 Furthermore, recent findings indicate
that PMSCs can regulate the secretion of IL-17,18,30 an
important cytokine secreted by T cells. Recent data have
implicated IL-17 and Th17 cells in the development of auto-
immunity and chronic rejection after lung transplantation in
animal models and in humans.32,33 Based on these reports
and our current findings, we suggest that PMSCs may be a
novel cell-based therapy for preventing/treating chronic
rejection after lung transplantation.
Our current findings show that administration of PMSCs
and PMSCCM produced an increase in Foxp3þ regulatory
T cells. Bharat and colleagues34 showed that regulatory
T cells limited Th1-autoimmunity by inducing IL-10–pro-
ducing T cells after human lung transplantation.34 More
recent data provide evidence that CD4þ Foxp3þ regulatory
T cells attenuate BO through the inhibition of effector
T cells and their function in a rat trachea transplantation
model.35 Our current data show that PMSC treatment in-
creases macrophage infiltration in the allografts. It is highly
possible that increase in Foxp3þ regulatory T cells may be,
at least partially, related to the increase in macrophage infil-
tration. In combination with our current results, we believe
that PMSCs reduce the development of BO not only through
suppression of CD3þ T-cell infiltration but also through
stimulating CD4þ Foxp3þ regulatory T cells.
Extrapolating the these findings in the HTT model to
application in lung transplant patients, we believe that intra-
tracheal injection of PMSCs or PMSCCMwould be roughly
comparable to an inhaled nebulized treatment in humans.
Although the HTT model is not a perfect representation
of this delivery mechanism, the observed effects with directgery c May 2014
Zhao et al Evolving Technology/Basic Sciencelocal administration are promising. Intravenous administra-
tion of PMSCs or PMSCCM, as studied in the HTT model
by Grove and colleagues,25 would be the other most logical
method of treatment. Despite the advantages discussed
earlier, there are some limiting factors to the clinical use
of these cells in patients. One of the barriers is the lack of
general consensus on a definition of these cells before
applying them to patients. Another barrier is the technical
difficulties in generating homogeneous lots because of
different cell sources and methods of isolation, sorting,
culturing, and characterizing. How the effects are evaluated
after administering the PMSCs is another challenge that
needs to worked out before using these cells clinically.
In summary, PMSCs have various characteristics similar
to bone marrow–derived MSCs, including the abilities to
protect against epithelial loss through promoting epithelial
progenitor cells, regulate inflammatory responses through
inhibition of neutrophil infiltration, to modulate immune re-
action through decreasing CD3þ T-cell infiltration, and in-
crease immune tolerance through inducing regulatory T-cell
production. All these events are important for the develop-
ment of BO. Therefore, PMSCs may provide a unique and
novel treatment option to prevent chronic rejection after
lung transplantation.E
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FIGUREE1. Local injection of PMSCs reduced the development of BO on day 28 after tracheal transplantation. A, Representative images of H&E-stained
tracheal allografts 28 days after transplantation. The magnification of the images is indicated on the left. B, Comparison of luminal obliteration of the
allografts with and without PMSC injection on day 28. Data shown are the mean  standard deviation. n ¼ 8. þPMSCs, Treated with PMSCs (1 3 106);
þPBS, treated with 13 PBS as control. PMSC, Placenta-derived human mesenchymal stem cells; PBS, phosphate-buffered saline.
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FIGURE E2. Loss of epithelial cells in allografts with and without local PMSC injection on day 14 after transplantation. A, Representative images
of H&E-stained histopathologic sections of tracheas treated with PMSCs (left column) and PBS (right column) at 14 days after transplantation. B, Bar graph
of epithelial cell loss in allografts with and without PMSC injection on day 14. Data shown are the mean  standard deviation. n ¼ 8. þPMSCs,
Intratracheally treated with PMSCs (1 3 106); þPBS, treated with 13 PBS as control. PMSC, Placenta–derived human mesenchymal stem cells;
PBS, phosphate-buffered saline.
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FIGURE E3. Immunohistochemical staining of CD3þ T cells (A) and CD4þ CD25þ Foxp3þ regulatory T cells (B) in the allografts treated with PMSCs
and PBS controls on day 14. Data shown are the mean  standard error of the mean. n ¼ 8. HPF, High-power field; PMSC, placenta–derived human
mesenchymal stem cells.
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FIGUREE4. Double immunofluorescent staining of P63 and CK14 in the tracheal allografts after intratracheal treatment with PMSCCMor blank medium
on day 14 after transplantation. Red color indicates positive staining of CK14; green color shows positive staining of P63; blue color indicates nuclei stained
with DAPI. The magnification of all images is 403. The merged images are indicated on the side. þPMSCCM, Treated with PMSCCM;þCONM, treated
with blank medium as control. DAPI, 4,6-diamidine-2-phenylindole dihydrochloride; PMSCCM, PMSC-conditioned medium; CONM, control media.
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FIGUREE5. Immunohistochemical staining of Foxp3þ regulatory T cells in allografts treated intratracheally with PMSCs and PBS controls on day 7 after
transplantation. A, Representative images of immunohistochemical staining of Foxp3þ regulatory T cells in allografts at 7 days after transplantation.
Images are at 403 magnification. þPMSCs, Treated with PMSCs (1 3 106); þPBS, treated with 13 PBS as control. B, Bar graph of Foxp3þ regulatory
T cells in the allografts. Data shown are the mean  standard error of the mean. n ¼ 8-12. Lu, Lumen; EP, epithelial layer; HPF, high-power field;
PMSC, placenta–derived human mesenchymal stem cells; PBS, phosphate-buffered saline.
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